SynthesisPloS one2026
Prevalence of medication-related problems and its predictors among cancer patients in Ethiopia: A systematic review and meta-analysis.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreventable medication-related problems intensify the risk associated with cancer care and no data was available to represent the burden of medication-related problems among cancer patients in Ethiopia. Hence, this study was aimed to estimate the pooled prevalence of medication-related problems and identify its predictors among cancer patients treated in Ethiopia.
methodsA systematic review and meta-analysis of studies retrieved from databases (Medline, EMBASE, Scopus, Cumulative Index to the Nursing and Allied Literature (CINAHL), Cochrane Library and Google Scholar) for relevant literature published before April, 2024 was made. We included observational studies conducted in Ethiopia that reported on the types, frequency, or risk factors of medication-related problems in cancer patients. Reviews, case reports, qualitative studies, and studies lacking relevant outcomes were excluded. The Newcastle-Ottawa quality assessment scale was used for quality assessment and the Egger's regression test and the Galbraith plot were used to evaluate publication bias. The national prevalence of medication-related problems was estimated using a random-effects model meta-analysis. Moreover, subgroup analysis and meta-regression analyses were done to explore the reasons of statistical heterogeneity. The study protocol has been registered with PROSPERO under number CRD42024505218.
resultsA total of 15 studies comprising of 3084 cancer patients were included in this study. The adjusted pooled prevalence of medication-related problems of cancer patients who experienced at least one medication-related problem was 48% [0.48 (95% CI: 0.39-0.57; I2 = 96%; p < 0.01)]. The study also revealed the pooled prevalence of non-adherence among the included studies to be 42% [0.42 (95% CI: 0.27-0.57; I2 = 97%; p < 0.01)]. The presence of comorbidities (AOR = 4.47, 95% CI: 3.26-5.69), complications (AOR = 5.78, 95% CI: 3.26-8.30) and polypharmacy (AOR = 3.75, 95% CI: 2.16-5.34) were found to be predictors of developing medication-related problems.
conclusionThis review found a high pooled prevalence of medication-related problems among cancer patients in Ethiopia, with predictors including comorbidities, complications and polypharmacy. About two-fifths of patients were not fully adherent to their prescribed cancer treatments. These findings highlight the need for targeted interventions to improve medication safety and adherence, and underscore the importance of future research to identify effective strategies for reducing MRPs in oncology settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.